Efficacy and safety of Enterprise stenting in the treatment of symptomatic middle cerebral artery atherosclerotic stenosis
Objective To investigate the efficacy and safety of Enterprise stenting in the treatment of symptomatic middle cerebral artery atherosclerotic stenosis.Methods Patients with symptomatic middle cerebral artery atherosclerotic stenosis underwent Enterprise stenting in the Department of Neurology,Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School from January 2020 to December 2022 were retrospectively included.The degree of residual stenosis,periprocedural complications,in-stent restenosis and stroke recurrence during follow-up were evaluated.Results A total of 75 patients were enrolled,including 55 males(73.3％),aged 58±9.7 years.The last preprocedural symptom was stroke in 65 cases(86.7％)and transient ischemic attack in 10 cases(13.3％).Sixty-seven patients(89.3％)had the Ml segment stenosis of the middle cerebral artery,and 8(10.7％)had the M2 segment stenosis.The degree of stenosis was 88.4％±8.90％.The median time from the last onset to stenting was 18 days(interquartile range,13-24 days).The procedural success rate was 100％,and the residual stenosis degree was 17.3％±6.1％.Four patients(5.3％)experienced periprocedural complications,including three ischemic strokes and one symptomatic intracranial hemorrhage.Sixty-one patients(81.3％)completed 3-to 12-month follow-up,of which 7 patients(11.5％)had in-stent restenosis and 2(3.3％)had recurrent ischemic stroke.Conclusion Enterprise stenting may be safe and effective in the treatment of symptomatic middle cerebral artery stenosis.
万方数据
